News|Videos|December 18, 2023
Revolutionizing Prostate Cancer Care: 2023’s Transformative Breakthroughs
Author(s)Rana R. McKay, MD, Tanya B. Dorff, MD
Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.
Advertisement
Advertisement
Related to this article
CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Mayo Clinic researchers reported data for minibeam radiotherapy for treatment-resistant cancers in or near the skin.
Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.
The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.
Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
2
FDA Clears sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC
3
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma
4
Phase 1 Data Support DAWN-303’s Evaluation of INCB161734 in Frontline KRAS G12D–Mutated PDAC
5